Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology
von Strauss und Torney M, Gueller U, Rezaeian F, Brosi P, Terracciano L, Zuber M. Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology. World J Surg 2012; 36:2300-4.
Oct 1, 2012Tissue banking in a regional hospital: a promising future concept? First report on fresh frozen tissue banking in a hospital without an integrated institute of pathology
Oct 1, 2012World J Surg 2012; 36:2300-4
von Strauss und Torney Marco, Gueller Ulrich, Rezaeian Farid, Brosi Philippe, Terracciano Luigi, Zuber Markus
Imaging of bone metastases in prostate cancer: an update
Langsteger W, Haim S, Knauer M, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M. Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging 2012; 56:447-58.
Oct 1, 2012Imaging of bone metastases in prostate cancer: an update
Oct 1, 2012Q J Nucl Med Mol Imaging 2012; 56:447-58
Langsteger W, Haim S, Knauer Michael, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M
Carbon dioxide insufflation in colonoscopy is safe: a prospective trial of 347 patients
Geyer M, Gueller U, Beglinger C. Carbon dioxide insufflation in colonoscopy is safe: a prospective trial of 347 patients. Diagn Ther Endosc 2012; 2012:692532.
Sep 29, 2012Carbon dioxide insufflation in colonoscopy is safe: a prospective trial of 347 patients
Sep 29, 2012Diagn Ther Endosc 2012; 2012:692532
Geyer M, Gueller Ulrich, Beglinger Ch
Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
Blum D, Köberle D, Ribi K, Hsu Schmitz S, Uitger U, Klingbiel D, Strasser F. Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC. BMC Palliat Care 2012; 11:19.
Sep 24, 2012Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
Sep 24, 2012BMC Palliat Care 2012; 11:19
Blum David, Köberle Dieter, Ribi Karin, Hsu Schmitz Shu-Fang, Uitger Urs, Klingbiel Dirk, Strasser Florian
Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas
Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, Seddon B, Strauss S. Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas. Clin Sarcoma Res 2012; 2:12.
Sep 21, 2012Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas
Sep 21, 2012Clin Sarcoma Res 2012; 2:12
Whelan Jeremy, Khan Atia, Sharma Anand, Rothermundt Christian, Dileo Palma, Michelagnoli Maria, Seddon Beatrice, Strauss Sandra
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S, Karow A, Lundberg P, Dirnhofer S, Lehmann T, Passweg J, Tichelli A, Skoda R, Rovó A. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report. Acta Haematol 2012; 129:23-5.
Sep 19, 2012JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Sep 19, 2012Acta Haematol 2012; 129:23-5
Girsberger Sabine, Karow Axel, Lundberg Pontus, Dirnhofer Stephan, Lehmann Thomas, Passweg Jakob R, Tichelli André, Skoda Radek C, Rovó Alicia
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
Sep 12, 2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Sep 12, 2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet 2012; 51:607-17.
Sep 1, 2012Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study
Sep 1, 2012Clin Pharmacokinet 2012; 51:607-17
Jörger Markus, Kraff Stefanie, Huitema Alwin D R, Feiss Gary, Moritz Berta, Schellens Jan H M, Beijnen Jos H, Jaehde Ulrich
B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.
Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch C, Hallek M, Wendtner C, Frenzel L. B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 2012; 120:3978-85.
Aug 27, 2012B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.
Aug 27, 2012Blood 2012; 120:3978-85
Schwamb Janine, Feldhaus Valeska, Baumann Michael, Patz Michaela, Brodesser Susanne, Brinker Reinhild, Claasen Julia, Pallasch Christian P, Hallek Michael, Wendtner Clemens-Martin, Frenzel Lukas P
Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Schmidt N, Hess V, Zumbrunn T, Rothermundt C, Bongartz G, Potthast S. Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. Eur Radiol 2012; 23:632-9.
Aug 24, 2012Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies
Aug 24, 2012Eur Radiol 2012; 23:632-9
Schmidt Noemi, Hess Viviane, Zumbrunn Thomas, Rothermundt Christian, Bongartz Georg, Potthast Silke
Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Jörger M, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann B, Ess S. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.
Aug 24, 2012Treatment of breast cancer in the elderly: a prospective, population-based Swiss study
Aug 24, 2012J Geriatr Oncol 2012; 4:39-47
Jörger Markus, Jundt G, Probst-Hensch N, Bordoni A, Konzelmann I, Bouchardy C, Vlastos G, Lütolf U, Rageth C, Frick H, Savidan A, Thürlimann Beat, Ess S
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Gillessen S, Speiser D, Laurent J, Kramer D, Liedert B, Mattiacci M, Omlin A, Sessa C, Beck J, Gallerani E, Gnad-Vogt U, Stupp R. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2012; 49:35-44.
Aug 20, 2012A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Aug 20, 2012Eur J Cancer 2012; 49:35-44
Gillessen Silke, Speiser Daniel E, Laurent Julien, Kramer Daniel, Liedert Bernd, Mattiacci Maria R, Omlin Aurelius, Sessa Cristiana, Beck Joachim, Gallerani Elisa, Gnad-Vogt Ulrike S, Stupp Roger
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober J, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer 2012; 107:956-60.
Aug 14, 2012Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
Aug 14, 2012Br J Cancer 2012; 107:956-60
Witzel I, Rack B, Meinhold-Heerlein I, Liedtke C, Karn T, Huober Jens, Zu Eulenburg C, Issa-Nummer Y, Untch M, Schem C, Mau C, Fasching P A, Loibl S, von Minckwitz G, Eidtmann H, Fehm T, Khandan F, Schmatloch S, Hauschild M, Bischoff J, Müller V
Safe and early discharge after colorectal surgery due to C-reactive protein: a diagnostic meta-analysis of 1832 patients
Warschkow R, Beutner U, Steffen T, Mueller S, Schmied B, Gueller U, Tarantino I. Safe and early discharge after colorectal surgery due to C-reactive protein: a diagnostic meta-analysis of 1832 patients. Ann Surg 2012; 256:245-50.
Aug 10, 2012Safe and early discharge after colorectal surgery due to C-reactive protein: a diagnostic meta-analysis of 1832 patients
Aug 10, 2012Ann Surg 2012; 256:245-50
Warschkow Rene, Beutner Ulrich, Steffen Thomas, Mueller Sascha, Schmied Bruno, Gueller Ulrich, Tarantino Ignazio
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Hartmann J, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm M, Heeger S, Bokemeyer C. A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer. Invest New Drugs 2012; 31:661-8.
Jul 26, 2012A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
Jul 26, 2012Invest New Drugs 2012; 31:661-8
Hartmann J T, Kollmannsberger C, Cascorbi I, Mayer F, Schittenhelm Marcus, Heeger S, Bokemeyer C
Dying is a transition
Renz M. Dying is a transition. Am J Hosp Palliat Care 2012; 30:283-90.
Jul 12, 2012Dying is a transition
Jul 12, 2012Am J Hosp Palliat Care 2012; 30:283-90
Renz Monika
Dying is a transition
Renz M. Dying is a transition. Am J Hosp Palliat Care 2012; 30:283-90.
Jul 12, 2012Dying is a transition
Jul 12, 2012Am J Hosp Palliat Care 2012; 30:283-90
Renz Monika
Dying is a transition
Renz M. Dying is a transition. Am J Hosp Palliat Care 2012; 30:283-90.
Jul 12, 2012Dying is a transition
Jul 12, 2012Am J Hosp Palliat Care 2012; 30:283-90
Renz Monika
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma 2012; 54:36-40.
Jul 9, 2012Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)
Jul 9, 2012Leuk Lymphoma 2012; 54:36-40
Wannesson Luciano, Samaras Panagiotis, Renner Christoph, Pabst Thomas, Lerch Erika, Hess Urs, Heim Dominik, Cerutti Alessandra, Cairoli Anne, Bargetzi Mario, Zucca Emanuele
Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Karlsson P, Gruber G, Goldhirsch A, Gelber R, Forbes J, Castiglione-Gertsch M, Crivellari D, Thürlimann B, Kovács A, Collins J, Lindtner J, Price K, Chua B, Cole B, International Breast Cancer Study Group. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol 2012; 23:2852-8.
Jul 9, 2012Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report
Jul 9, 2012Ann Oncol 2012; 23:2852-8
Karlsson P, Gruber G, Goldhirsch A, Gelber R D, Forbes J F, Castiglione-Gertsch M, Crivellari D, Thürlimann Beat, Kovács A, Collins J P, Lindtner J, Price K N, Chua B H, Cole B F, International Breast Cancer Study Group